Literature DB >> 30231352

More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments.

Daniela Katz1, Emanuela Palmerini1, Seth M Pollack1.   

Abstract

Sarcomas are a diverse group of cancers with mesenchymal origin. Although sarcomas comprise less than 1% of cancers, there are more than 50 different subtypes that are quite different from one another in terms of both their biology and clinical behavior. Historically, the need for adequate patient numbers in clinical trials has pushed sarcoma researchers to lump these very different malignancies together and treat the patients using a "one-size-fits-all" approach. However, with improvements in our scientific understanding, we are finally ready for a histology-tailored therapeutic approach to these complex diseases. In this review, we discuss key advances in our understanding of the biology underlying selected sarcoma subtypes and how targeting these subtypes is relevant therapeutically with respect to both molecularly targeted agents as well as immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30231352     DOI: 10.1200/EDBK_205423

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  15 in total

1.  Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.

Authors:  Ashley M Fuller; Ann DeVine; Ileana Murazzi; Nicola J Mason; Kristy Weber; T S Karin Eisinger-Mathason
Journal:  Cell Oncol (Dordr)       Date:  2022-10-01       Impact factor: 7.051

Review 2.  Novel Effects of Statins on Cancer via Autophagy.

Authors:  Daniela Mengual; Luz Elena Medrano; Wendy Villamizar-Villamizar; Estefanie Osorio-Llanes; Evelyn Mendoza-Torres; Samir Bolívar
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

3.  Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features.

Authors:  Luan Nguyen; Arne Van Hoeck; Edwin Cuppen
Journal:  Nat Commun       Date:  2022-07-11       Impact factor: 17.694

Review 4.  Update on systemic therapy for advanced soft-tissue sarcoma.

Authors:  A Smrke; Y Wang; C Simmons
Journal:  Curr Oncol       Date:  2020-02-01       Impact factor: 3.677

5.  RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Casey Pulliam; Chandra K Maharjan; Allison Moreno Samayoa; Heather J Major; Kendall E Cornick; Vickie Knepper-Adrian; Rajesh Khanna; Jessica C Sieren; Mariah R Leidinger; David K Meyerholz; K D Zamba; Jill M Weimer; Rebecca D Dodd; Benjamin W Darbro; Munir R Tanas; Dawn E Quelle
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

6.  Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation.

Authors:  Mitra Nair; Maninder Khosla; Yoshihiro Otani; Margaret Yeh; Flora Park; Toshihiko Shimizu; Jin Muk Kang; Chelsea Bolyard; Jun-Ge Yu; Yeshavanth Kumar Banasavadi-Siddegowda; Gonzalo Lopez; Balveen Kaur; Raphael E Pollock; Tae Jin Lee; Matthew Old; Ji Young Yoo
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

7.  The Impact of Surgical Margins and Adjuvant Radiotherapy in Patients with Undifferentiated Pleomorphic Sarcomas of the Extremities: A Single-Institutional Analysis of 192 Patients.

Authors:  Ole Goertz; Andreas Pieper; Leon von der Lohe; Ingo Stricker; Mehran Dadras; Björn Behr; Marcus Lehnhardt; Kamran Harati
Journal:  Cancers (Basel)       Date:  2020-02-05       Impact factor: 6.639

8.  Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices.

Authors:  Eric Nadler; Kathleen Aguilar; Chuck Wentworth; Marley Boyd; E Susan Amirian; Scott Barker; Pearl French; Thomas Wilson; Lisa M Hess
Journal:  Sarcoma       Date:  2020-02-28

Review 9.  The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches.

Authors:  Anna Koumarianou; Jose Duran-Moreno
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

Review 10.  Immunotherapy for sarcomas: new frontiers and unveiled opportunities.

Authors:  Harsimrat Kaur Birdi; Anna Jirovec; Serena Cortés-Kaplan; Jean-Simon Diallo; Michele Ardolino; Joel Werier; Carolyn Nessim
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 12.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.